137 related articles for article (PubMed ID: 18180382)
1. BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia.
Ban K; Gao Y; Amin HM; Howard A; Miller C; Lin Q; Leng X; Munsell M; Bar-Eli M; Arlinghaus RB; Chandra J
Blood; 2008 Mar; 111(5):2904-8. PubMed ID: 18180382
[TBL] [Abstract][Full Text] [Related]
2. Expression and activity of Fyn mediate proliferation and blastic features of chronic myelogenous leukemia.
Singh MM; Howard A; Irwin ME; Gao Y; Lu X; Multani A; Chandra J
PLoS One; 2012; 7(12):e51611. PubMed ID: 23284724
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors.
Grosso S; Puissant A; Dufies M; Colosetti P; Jacquel A; Lebrigand K; Barbry P; Deckert M; Cassuto JP; Mari B; Auberger P
Mol Cancer Ther; 2009 Jul; 8(7):1924-33. PubMed ID: 19567819
[TBL] [Abstract][Full Text] [Related]
4. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
[TBL] [Abstract][Full Text] [Related]
5. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.
Bartholomeusz GA; Talpaz M; Kapuria V; Kong LY; Wang S; Estrov Z; Priebe W; Wu J; Donato NJ
Blood; 2007 Apr; 109(8):3470-8. PubMed ID: 17202319
[TBL] [Abstract][Full Text] [Related]
6. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.
Ng KP; Manjeri A; Lee KL; Huang W; Tan SY; Chuah CT; Poellinger L; Ong ST
Blood; 2014 May; 123(21):3316-26. PubMed ID: 24705490
[TBL] [Abstract][Full Text] [Related]
7. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
8. Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.
Fenouille N; Puissant A; Dufies M; Robert G; Jacquel A; Ohanna M; Deckert M; Pasquet JM; Mahon FX; Cassuto JP; Raynaud S; Tartare-Deckert S; Auberger P
Cancer Res; 2010 Dec; 70(23):9659-70. PubMed ID: 21098700
[TBL] [Abstract][Full Text] [Related]
9. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
Hu Y; Liu Y; Pelletier S; Buchdunger E; Warmuth M; Fabbro D; Hallek M; Van Etten RA; Li S
Nat Genet; 2004 May; 36(5):453-61. PubMed ID: 15098032
[TBL] [Abstract][Full Text] [Related]
10. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
Nguyen TK; Rahmani M; Harada H; Dent P; Grant S
Blood; 2007 May; 109(9):4006-15. PubMed ID: 17218385
[TBL] [Abstract][Full Text] [Related]
11. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.
Zhao F; Mancuso A; Bui TV; Tong X; Gruber JJ; Swider CR; Sanchez PV; Lum JJ; Sayed N; Melo JV; Perl AE; Carroll M; Tuttle SW; Thompson CB
Oncogene; 2010 May; 29(20):2962-72. PubMed ID: 20228846
[TBL] [Abstract][Full Text] [Related]
12. BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.
Roy S; Jørgensen HG; Roy P; Abed El Baky M; Melo JV; Strathdee G; Holyoake TL; Bartholomew C
Br J Haematol; 2012 May; 157(4):446-56. PubMed ID: 22372463
[TBL] [Abstract][Full Text] [Related]
13. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
14. Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.
Doki N; Kitaura J; Uchida T; Inoue D; Kagiyama Y; Togami K; Isobe M; Ito S; Maehara A; Izawa K; Kato N; Oki T; Harada Y; Nakahara F; Harada H; Kitamura T
Int J Hematol; 2012 Feb; 95(2):167-75. PubMed ID: 22189847
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
[TBL] [Abstract][Full Text] [Related]
17. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
Nimmanapalli R; Fuino L; Stobaugh C; Richon V; Bhalla K
Blood; 2003 Apr; 101(8):3236-9. PubMed ID: 12446442
[TBL] [Abstract][Full Text] [Related]
18. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
[TBL] [Abstract][Full Text] [Related]
19. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
[TBL] [Abstract][Full Text] [Related]
20. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
